|
US6749853B1
(en)
*
|
1992-03-05 |
2004-06-15 |
Board Of Regents, The University Of Texas System |
Combined methods and compositions for coagulation and tumor treatment
|
|
US5965132A
(en)
*
|
1992-03-05 |
1999-10-12 |
Board Of Regents, The University Of Texas System |
Methods and compositions for targeting the vasculature of solid tumors
|
|
US7105159B1
(en)
|
1992-11-05 |
2006-09-12 |
Sloan-Kettering Institute For Cancer Research |
Antibodies to prostate-specific membrane antigen
|
|
US7070782B1
(en)
*
|
1992-11-05 |
2006-07-04 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen
|
|
US6953668B1
(en)
|
1992-11-05 |
2005-10-11 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen
|
|
WO1996026272A1
(en)
|
1995-02-24 |
1996-08-29 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen and uses thereof
|
|
US6569432B1
(en)
*
|
1995-02-24 |
2003-05-27 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen and uses thereof
|
|
US20040253246A1
(en)
*
|
1996-02-23 |
2004-12-16 |
Israeli Ron S. |
Prostate-specific membrane antigen and uses thereof
|
|
US6962981B1
(en)
|
1996-03-25 |
2005-11-08 |
Medarex, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
|
US6150508A
(en)
*
|
1996-03-25 |
2000-11-21 |
Northwest Biotherapeutics, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
|
US7381407B1
(en)
*
|
1996-03-25 |
2008-06-03 |
Medarex, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
|
US6136311A
(en)
*
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
|
US6759515B1
(en)
*
|
1997-02-25 |
2004-07-06 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
|
US20060269532A1
(en)
*
|
1997-02-25 |
2006-11-30 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
|
US20060024301A1
(en)
*
|
1997-02-25 |
2006-02-02 |
Corixa Corporation |
Prostate-specific polypeptides and fusion polypeptides thereof
|
|
US6207805B1
(en)
|
1997-07-18 |
2001-03-27 |
University Of Iowa Research Foundation |
Prostate cell surface antigen-specific antibodies
|
|
US6232287B1
(en)
*
|
1998-03-13 |
2001-05-15 |
The Burnham Institute |
Molecules that home to various selected organs or tissues
|
|
US6200765B1
(en)
|
1998-05-04 |
2001-03-13 |
Pacific Northwest Cancer Foundation |
Non-invasive methods to detect prostate cancer
|
|
FR2791573B1
(fr)
*
|
1999-03-30 |
2003-04-11 |
Pf Medicament |
Utilisation d'un extrait de serenoa repens pour la fabrication d'un medicament destine au traitement du cancer de la prostate
|
|
ES2277846T3
(es)
*
|
1999-07-29 |
2007-08-01 |
Medarex, Inc. |
Anticuerpos monoclonales humanos para antigeno prostatico especifico.
|
|
EP1710256A1
(en)
*
|
1999-07-29 |
2006-10-11 |
Medarex, Inc. |
Human monoclonal antibodies to prostate specific membrane antigen
|
|
US6653129B1
(en)
*
|
1999-09-13 |
2003-11-25 |
The Regents Of The University Of Colorado |
Method for isolation of cells from a solution
|
|
US20080153119A1
(en)
*
|
1999-09-24 |
2008-06-26 |
Schebo Biotech Ag |
Detecting the presence of pyruvate kinase isoenzyme in feces
|
|
JP5074652B2
(ja)
|
2000-02-08 |
2012-11-14 |
ライスユニバーシティ |
治療法および診断法において使用される光学活性なナノ粒子
|
|
US6379550B1
(en)
*
|
2000-07-24 |
2002-04-30 |
Health Research, Inc. |
Method for detecting PSA and its molecular forms using thiophilic gel
|
|
US7048931B1
(en)
|
2000-11-09 |
2006-05-23 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
|
US7468354B2
(en)
|
2000-12-01 |
2008-12-23 |
Genspera, Inc. |
Tissue specific prodrugs
|
|
EP1390069A1
(en)
*
|
2001-05-30 |
2004-02-25 |
Cornell Research Foundation, Inc. |
Endopeptidase/anti-psma antibody fusion proteins for treatment of cancer
|
|
US7514078B2
(en)
*
|
2001-06-01 |
2009-04-07 |
Cornell Research Foundation, Inc. |
Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
|
|
US7666414B2
(en)
*
|
2001-06-01 |
2010-02-23 |
Cornell Research Foundation, Inc. |
Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
|
|
CA2447695C
(en)
|
2001-06-01 |
2015-02-24 |
Cornell Research Foundation, Inc. |
Modified antibodies to prostate-specific membrane antigen and uses thereof
|
|
US20060073530A1
(en)
*
|
2001-08-15 |
2006-04-06 |
Olaf Schneewind |
Methods and compositions involving sortase B
|
|
AU2002359244A1
(en)
*
|
2001-09-05 |
2003-04-28 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of |
Imaging the activity of extracellular proteases in cells using mutant anthrax toxin protective antigens that are cleaved by specific extracellular proteases
|
|
IL159422A0
(en)
*
|
2001-09-20 |
2004-06-01 |
Cornell Res Foundation Inc |
Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
|
|
US20030129193A1
(en)
*
|
2001-09-27 |
2003-07-10 |
Board Of Regents, The University Of Texas System And Peregrine Pharmaceuticals, Inc. |
Combined methods for tumor vasculature coaguligand treatment
|
|
WO2003034903A2
(en)
*
|
2001-10-23 |
2003-05-01 |
Psma Development Company, L.L.C. |
Psma antibodies and protein multimers
|
|
US20050215472A1
(en)
|
2001-10-23 |
2005-09-29 |
Psma Development Company, Llc |
PSMA formulations and uses thereof
|
|
US20040161776A1
(en)
*
|
2001-10-23 |
2004-08-19 |
Maddon Paul J. |
PSMA formulations and uses thereof
|
|
US7591994B2
(en)
|
2002-12-13 |
2009-09-22 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
|
US7767803B2
(en)
*
|
2002-06-18 |
2010-08-03 |
Archemix Corp. |
Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
|
|
DE60335383D1
(de)
|
2002-07-15 |
2011-01-27 |
Univ Texas |
Antikörper mit bindung an anionische phospholipide und aminophospholipide und ihre verwendung bei der behandlung von virusinfektionen
|
|
US7390898B2
(en)
|
2002-08-02 |
2008-06-24 |
Immunogen Inc. |
Cytotoxic agents containing novel potent taxanes and their therapeutic use
|
|
ES2314272T3
(es)
*
|
2003-01-10 |
2009-03-16 |
Millennium Pharmaceuticals, Inc. |
Metodos para el diagnostico y el tratamiento del cancer.
|
|
CA2514419A1
(en)
|
2003-01-28 |
2004-08-12 |
Proscan Rx Pharma Inc. |
Prostate cancer diagnosis and treatment
|
|
EP1610818A4
(en)
*
|
2004-03-03 |
2007-09-19 |
Millennium Pharm Inc |
MODIFIED ANTIBODIES AGAINST A PROSTATE-SPECIFIC MEMBRANE-ANTIGEN AND USE THEREOF
|
|
US20080241262A1
(en)
*
|
2004-03-29 |
2008-10-02 |
The University Of Houston System |
Nanoshells and Discrete Polymer-Coated Nanoshells, Methods For Making and Using Same
|
|
EP1756166A4
(en)
*
|
2004-04-19 |
2008-08-27 |
Proscan Rx Pharma |
DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
|
|
WO2006051542A1
(en)
*
|
2004-11-12 |
2006-05-18 |
Kpe Ltd. |
Nanoparticle mediated ultrasound therapy and diagnostic imaging
|
|
WO2006086345A2
(en)
*
|
2005-02-07 |
2006-08-17 |
The Trustees Of Columbia University In The City Of New York |
Methods to treat or prevent hormone-resistant prostate cancer using sirna specific for protocadherin-pc, or other inhibitors of protocadherin-pc expression or activity
|
|
CA2598454C
(en)
*
|
2005-02-18 |
2013-04-09 |
Medarex, Inc. |
Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
|
|
ES2386366T3
(es)
*
|
2005-02-18 |
2012-08-17 |
Medarex, Inc. |
Anticuerpo monoclonal humano contra el antígeno de membrana específico de la próstata (PSMA)
|
|
AU2006220621A1
(en)
*
|
2005-03-07 |
2006-09-14 |
Archemix Corp. |
Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
|
|
EP1726650A1
(en)
*
|
2005-05-27 |
2006-11-29 |
Universitätsklinikum Freiburg |
Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
|
|
US7736647B2
(en)
*
|
2005-06-15 |
2010-06-15 |
Monoclonal Antibodies Therapeutics |
Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
|
|
AU2006262231B2
(en)
*
|
2005-06-20 |
2013-01-24 |
Psma Development Company, Llc |
PSMA antibody-drug conjugates
|
|
EP1934261B1
(en)
*
|
2005-09-26 |
2014-10-29 |
Medarex, L.L.C. |
Human monoclonal antibodies to cd70
|
|
SI1964852T1
(sl)
*
|
2005-12-20 |
2013-09-30 |
Sbi Biotech Co. Ltd. |
Proti-ilt7 protitelo
|
|
ZA200900545B
(en)
*
|
2006-07-18 |
2010-03-31 |
Sanofi Aventis |
Antagonist antibody against EPHA2 for the treatment of cancer
|
|
US20100150950A1
(en)
*
|
2006-12-14 |
2010-06-17 |
Medarex, Inc. |
Human antibodies that bind cd70 and uses thereof
|
|
US20090029408A1
(en)
*
|
2007-07-25 |
2009-01-29 |
Wyeth |
Methods for Characterizing Cell Proximity
|
|
WO2009046294A2
(en)
|
2007-10-03 |
2009-04-09 |
Cornell University |
Treatment of proliferative disorders using antibodies to psma
|
|
WO2009127046A1
(en)
*
|
2008-04-14 |
2009-10-22 |
Proscan Rx Pharma Inc. |
Prostate specific membrane antigen antibodies and antigen binding fragments
|
|
EP2326350B1
(en)
|
2008-09-08 |
2013-09-04 |
Psma Development Company, L.L.C. |
Compounds for killing psma-expressing, taxane-resistant cancer cells
|
|
US20100082438A1
(en)
*
|
2008-10-01 |
2010-04-01 |
Ronnie Jack Garmon |
Methods and systems for customer performance scoring
|
|
MD35Z
(ro)
*
|
2008-12-02 |
2010-01-31 |
Василе ЖОВМИР |
Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
|
|
MD36Z
(ro)
*
|
2008-12-02 |
2010-01-31 |
Василе ЖОВМИР |
Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
|
|
MD23Z
(ro)
*
|
2008-12-02 |
2010-01-31 |
Василе ЖОВМИР |
Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
|
|
MD24Z
(ro)
*
|
2008-12-02 |
2010-01-31 |
Василе ЖОВМИР |
Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
|
|
PL3912643T3
(pl)
|
2009-02-13 |
2023-01-23 |
Immunomedics Inc. |
Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
|
|
JP5906090B2
(ja)
|
2009-02-17 |
2016-04-20 |
コーネル・リサーチ・ファンデーション・インコーポレイテッドＣｏｒｎｅｌｌ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ， Ｉｎｃｏｒｐｏｒａｔｅｄ |
癌の診断のための方法およびキットならびに治療価の推定
|
|
CA2769444A1
(en)
|
2009-05-19 |
2010-11-25 |
Aic Blab Company |
Composite current collector and methods therefor
|
|
US8221753B2
(en)
|
2009-09-30 |
2012-07-17 |
Tracon Pharmaceuticals, Inc. |
Endoglin antibodies
|
|
IN2012DN03354A
(enExample)
|
2009-12-02 |
2015-10-23 |
Immunomedics Inc |
|
|
CA3040276A1
(en)
|
2009-12-02 |
2011-06-09 |
Imaginab, Inc. |
J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
|
|
CA2793753C
(en)
|
2010-03-26 |
2018-06-05 |
Memorial Sloan-Kettering Cancer Center |
Antibodies to muc16 and methods of use thereof
|
|
JP5702944B2
(ja)
*
|
2010-03-31 |
2015-04-15 |
独立行政法人国立がん研究センター |
バイオマーカー
|
|
WO2011133555A2
(en)
|
2010-04-20 |
2011-10-27 |
The Research Foundation Of State University Of New York |
Compositions and methods for inhibiting matrix metalloproteinase (mmp)-mediated cell migration
|
|
RU2012148816A
(ru)
*
|
2010-05-07 |
2014-06-20 |
Ф. Хоффманн-Ля Рош Аг |
Метод диагностики для определения клеток ex vivo
|
|
WO2012075173A2
(en)
|
2010-12-01 |
2012-06-07 |
Board Of Regents The University Of Texas System |
Compositions and method for deimmunization of proteins
|
|
WO2012106368A2
(en)
|
2011-01-31 |
2012-08-09 |
The Regents Of The University Of California |
Methods for inhibiting prostate cancer
|
|
US8314566B2
(en)
*
|
2011-02-22 |
2012-11-20 |
Quarkstar Llc |
Solid state lamp using light emitting strips
|
|
AU2012250924B2
(en)
|
2011-05-02 |
2017-05-25 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
|
EP3536700A1
(en)
|
2012-06-07 |
2019-09-11 |
Ambrx, Inc. |
Prostate-specific membrane antigen antibody drug conjugates
|
|
MX2014015205A
(es)
|
2012-06-14 |
2015-08-14 |
Ambrx Inc |
Anticuerpos anti-psma conjugados a polipeptidos de ligando de receptor nuclear.
|
|
AU2013302696B9
(en)
|
2012-08-14 |
2018-08-09 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
|
UA115789C2
(uk)
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
|
JP6340006B2
(ja)
*
|
2012-10-05 |
2018-06-06 |
コーネル ユニヴァーシティー |
アンドロゲン抑制、前立腺特異的膜抗原、および条件的に増大した脆弱性の概念
|
|
DK2839860T3
(da)
|
2012-10-12 |
2019-06-17 |
Medimmune Ltd |
Pyrrolobenzodiazepiner og konjugater deraf
|
|
CN107753954A
(zh)
|
2012-12-13 |
2018-03-06 |
免疫医疗公司 |
功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
|
|
US11242399B2
(en)
|
2013-02-19 |
2022-02-08 |
Adienne S.A. |
Anti-CD26 antibodies
|
|
ES2687439T3
(es)
|
2013-03-13 |
2018-10-25 |
Medimmune Limited |
Pirrolobenzodiazepinas y conjugados de las mismas
|
|
CA2904357C
(en)
|
2013-03-15 |
2020-09-22 |
Intrinsic Lifesciences Llc |
Anti-hepcidin antibodies and uses thereof
|
|
JP6908964B2
(ja)
|
2013-10-18 |
2021-07-28 |
ピーエスエムエー ディベロップメント カンパニー，エルエルシー |
Ｐｓｍａリガンドコンジュゲートによる併用療法
|
|
WO2015073896A2
(en)
|
2013-11-15 |
2015-05-21 |
Psma Development Company, Llc |
Biomarkers for psma targeted therapy for prostate cancer
|
|
ES2978993T3
(es)
|
2014-02-21 |
2024-09-23 |
Ibc Pharmaceuticals Inc |
Terapia de enfermedades mediante la inducción de la respuesta inmunitaria a las células que expresan Trop-2
|
|
CA2935748A1
(en)
|
2014-02-25 |
2015-09-03 |
Immunomedics, Inc. |
Humanized rfb4 anti-cd22 antibody
|
|
DK3151865T3
(da)
|
2014-05-22 |
2021-10-25 |
Byondis Bv |
Stedsspecifik konjugation af linker medicin til antistof og resulterende adcs
|
|
US9580495B2
(en)
|
2014-06-24 |
2017-02-28 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
|
EP3193940A1
(en)
|
2014-09-10 |
2017-07-26 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
CA2961917A1
(en)
|
2014-09-22 |
2016-03-31 |
Intrinsic Lifesciences Llc |
Humanized anti-hepcidin antibodies and uses thereof
|
|
PL3204018T3
(pl)
|
2014-10-07 |
2022-01-03 |
Immunomedics, Inc. |
Neoadiuwantowe zastosowanie koniugatów przeciwciało-lek
|
|
AU2015346444A1
(en)
|
2014-11-12 |
2017-05-04 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
|
US9926375B2
(en)
|
2014-11-12 |
2018-03-27 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
|
CN104447955B
(zh)
*
|
2014-11-23 |
2018-04-20 |
南京市第一医院 |
一种与psma膜外区靶向性结合的多肽及其应用
|
|
EP3064507A1
(en)
|
2015-03-06 |
2016-09-07 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
|
|
US10722523B2
(en)
|
2015-03-17 |
2020-07-28 |
The Regents Of The University Of California |
Chemoimmunotherapy for epithelial cancer
|
|
KR102618312B1
(ko)
|
2015-03-17 |
2023-12-28 |
메모리얼 슬로안 케터링 캔서 센터 |
항muc16 항체 및 그의 용도
|
|
EP3286224A4
(en)
|
2015-04-22 |
2018-11-14 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
|
|
EP3297672B1
(en)
|
2015-05-21 |
2021-09-01 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
PT3313443T
(pt)
|
2015-06-25 |
2023-08-30 |
Immunomedics Inc |
Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
|
|
PL3316885T3
(pl)
|
2015-07-01 |
2021-12-06 |
Immunomedics, Inc. |
Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
|
|
JOP20160154B1
(ar)
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
|
CN108136012B
(zh)
|
2015-08-07 |
2022-10-04 |
伊麦吉纳博公司 |
靶向分子的抗原结合构建体
|
|
EP3192810A1
(en)
*
|
2016-01-14 |
2017-07-19 |
Deutsches Krebsforschungszentrum |
Psma binding antibody and uses thereof
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
KR102530742B1
(ko)
|
2016-05-20 |
2023-05-09 |
하푼 테라퓨틱스, 인크. |
단일 도메인 혈청 알부민 결합 단백질
|
|
HRP20251020T1
(hr)
|
2016-05-20 |
2025-10-24 |
Harpoon Therapeutics, Inc. |
Proteini s jednolančanim varijabilnim fragmentom koji vežu cd3
|
|
CN117534764A
(zh)
|
2016-06-06 |
2024-02-09 |
阿布泽纳(英国)有限公司 |
抗体、其用途及其缀合物
|
|
GB201614162D0
(en)
|
2016-08-18 |
2016-10-05 |
Polytherics Ltd |
Antibodies, uses thereof and conjugates thereof
|
|
CN109862919A
(zh)
|
2016-10-11 |
2019-06-07 |
免疫医疗有限公司 |
抗体-药物缀合物联合免疫介导的治疗剂
|
|
KR102275008B1
(ko)
|
2016-11-23 |
2021-07-13 |
하푼 테라퓨틱스, 인크. |
전립선 특이 막 항원 결합 단백질
|
|
JP7215997B2
(ja)
|
2016-11-23 |
2023-01-31 |
ハープーン セラピューティクス，インク． |
前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法
|
|
WO2018147960A1
(en)
|
2017-02-08 |
2018-08-16 |
Imaginab, Inc. |
Extension sequences for diabodies
|
|
WO2018160754A2
(en)
|
2017-02-28 |
2018-09-07 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
US10730954B2
(en)
|
2017-05-12 |
2020-08-04 |
Harpoon Therapeutics, Inc. |
MSLN targeting trispecific proteins and methods of use
|
|
SG10202107880XA
(en)
|
2017-05-12 |
2021-09-29 |
Harpoon Therapeutics Inc |
Mesothelin binding proteins
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
CA3078969A1
(en)
|
2017-10-13 |
2019-04-18 |
Harpoon Therapeutics, Inc. |
Trispecific proteins and methods of use
|
|
AU2018360637A1
(en)
|
2017-11-04 |
2020-05-14 |
Sona Nanotech Inc. |
Metal nanoparticles and methods of making same
|
|
KR20200130709A
(ko)
|
2018-03-06 |
2020-11-19 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
전립선-특이 막 항원 car 및 이의 사용 방법
|
|
SG11202009670RA
(en)
*
|
2018-03-29 |
2020-10-29 |
Ambrx Inc |
Humanized anti-prostate-specific membrane antigen (psma) antibody drug conjugates
|
|
MX2020012217A
(es)
|
2018-05-14 |
2021-03-02 |
Harpoon Therapeutics Inc |
Porción de unión para activación condicional de moléculas de inmunoglobulina.
|
|
CA3098103A1
(en)
|
2018-05-23 |
2019-11-28 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
EP3587454A1
(en)
*
|
2018-06-27 |
2020-01-01 |
Albert-Ludwigs-Universität Freiburg |
Chimeric antigen receptors that bind to prostate specific membrane antigen
|
|
EP3830132B1
(en)
|
2018-07-31 |
2022-11-23 |
Heidelberg Pharma Research GmbH |
Humanized antibodies against psma
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
CN119306844A
(zh)
|
2018-09-25 |
2025-01-14 |
哈普恩治疗公司 |
Dll3结合蛋白及使用方法
|
|
CN119455003A
(zh)
|
2019-02-12 |
2025-02-18 |
Ambrx公司 |
包含抗体-tlr激动剂缀合物的组合物、方法和用途
|
|
USD925928S1
(en)
|
2019-03-01 |
2021-07-27 |
Simplehuman, Llc |
Vanity mirror
|
|
WO2020232303A1
(en)
|
2019-05-14 |
2020-11-19 |
Harpoon Therapeutics, Inc. |
EpCAM BINDING PROTEINS AND METHODS OF USE
|
|
BR112022016550A2
(pt)
|
2020-02-21 |
2022-11-16 |
Harpoon Therapeutics Inc |
Proteínas de ligação a flt3 e métodos de uso
|
|
WO2022010797A2
(en)
|
2020-07-07 |
2022-01-13 |
Bionecure Therapeutics, Inc. |
Novel maytansinoids as adc payloads and their use for the treatment of cancer
|
|
US20230372528A1
(en)
|
2020-10-16 |
2023-11-23 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
|
CN112285082A
(zh)
*
|
2020-10-28 |
2021-01-29 |
上海睿钰生物科技有限公司 |
一种基于细胞直径评价细胞杀伤效力的方法及其应用
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
EP4342497A1
(en)
|
2021-05-10 |
2024-03-27 |
Kawasaki Institute of Industrial Promotion |
Antibody having reduced binding affinity for antigen
|
|
CN117980327A
(zh)
|
2021-11-03 |
2024-05-03 |
杭州多禧生物科技有限公司 |
抗体的特异性偶联
|
|
TW202442689A
(zh)
|
2023-03-03 |
2024-11-01 |
美商亞森諾生物科學公司 |
靶向ｐｓｍａ及ｃａ９之系統
|